Luk H. Vandenberghe

Luk H. Vandenberghe has a diverse range of work experience in the medical and biotechnology field. Luk H. started their career in 2011 as a Co-Founder of GenSight Biologics. In 2012, they joined the Schepens Eye Research Institute as an Assistant Scientist and also worked as an Investigator at the Ocular Genomics Institute, Massachusetts Eye and Ear Infirmary and Harvard Medical School. In 2013, they became an Assistant Professor at Harvard Medical School and later transitioned to the role of Associate Professor.

Luk H. Vandenberghe also held various positions in different organizations. In 2014, they became the Director of the Grousbeck Gene Therapy Center and in 2017, they joined the Broad Institute of MIT and Harvard as an Associate Member. Luk H. also co-founded Odylia Therapeutics and Akouos, serving as a Member of the Board of Directors and Scientific Advisory Board respectively. In 2019, they became a Scientific Founder and Board Member at Affinia Therapeutics.

In 2020, Luk H. Vandenberghe took on the role of Director of the Board of Directors at Addgene. Throughout their career, they have demonstrated a strong dedication to medical research and the development of innovative therapies in the field of genetics and ophthalmology.

Luk H. Vandenberghe completed their education at KU Leuven, where they obtained a Master of Science (M.S.) degree in Cellular and Genetic Biotechnology from 1995 to 2000. Luk H. further pursued their academic interests and earned a Doctor of Philosophy (Ph.D.) degree in Molecular Medicine from KU Leuven between 2002 and 2007.